Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert a total of 102 million unlisted shares held by 20 shareholders into H-shares on a one-to-one basis, which represents approximately 26.35% of the company's total issued shares as of the announcement date [1] Group 1 - The conversion of unlisted shares into H-shares is aimed at increasing liquidity and potentially enhancing shareholder value [1] - The application to the regulatory body indicates the company's strategic move towards expanding its capital market presence [1] - The conversion process reflects the company's ongoing efforts to align with market practices and improve its financial structure [1]

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert a total of 102 million unlisted shares held by 20 shareholders into H-shares on a one-to-one basis, representing approximately 26.35% of the company's total issued shares as of the announcement date [1] Group 1 - The conversion involves 20 shareholders and a total of 102 million unlisted shares [1] - The conversion will result in the issuance of H-shares, which are traded on the Hong Kong Stock Exchange [1] - The newly converted shares will account for about 26.35% of the company's total issued shares as of the announcement date [1]

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert approximately 101.7 million unlisted shares held by 20 shareholders into H-shares based on a one-to-one ratio, which represents about 26.35% of the total issued shares as of the announcement date [1] Group 1 - The conversion involves 20 shareholders and a total of approximately 101.7 million unlisted shares [1] - The conversion will result in these shares being transformed into H-shares, expanding the company's capital structure [1] - The application has been submitted to the China Securities Regulatory Commission for approval [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 本公告乃派格生物醫藥（杭州）股份有限公司（「本公司」）根據香港聯合交易所有限 公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章 證券及期貨條例第XIVA部作出。 茲提述中國證券監督管理委員會（「中國證監會」）於2023年8月10日發佈的《H股公 司境內未上市股份申請「全流通」業務指引》（中國證監會公告[2023]50號）（「該指 引」），內容有關H股於聯交所上市的公司申請境內未上市股份（定義見該指引）在 聯交所流通的程序。 根據該指引，本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司已於2025年 11月28日就按一比一的基準將本公司20名股東持有的合共101,702,051股未上市股 份（「未上市股份」）轉換為本公司H股 ...

Core Viewpoint - The stock of Pagoda Biopharmaceuticals-B (02565.HK) opened over 7% higher on November 27, closing at HKD 70.00 per share, an increase of 7.03% due to the announcement of an extended lock-up period by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [2] Group 1: Lock-up Period Extension - Yizhe Kangrui has agreed not to reduce its holdings of H-shares from the original lock-up expiration date until December 31, 2025, extending the lock-up period by 35 days [3] - The extension reflects Yizhe Kangrui's confidence in Pagoda Biopharmaceuticals' technological advancements and significant progress in major clinical milestones [2][3] - Yizhe Kangrui currently holds 9.5845 million H-shares, representing approximately 3.43% of the total issued H-shares of the company [3] Group 2: Company Background and Recent Developments - Pagoda Biopharmaceuticals, established in 2008, focuses on the research and development of innovative therapies for chronic diseases, particularly in the field of metabolic disorders [5] - The company recently received approval for its first product, PB-119 (Vepidna Injection), aimed at improving blood sugar control in adults with type 2 diabetes [6] - Since its listing, Pagoda Biopharmaceuticals has seen a stock price increase of 438.46% over 129 trading days from May 27 to the present [6] Group 3: Financial Performance and Market Outlook - Pagoda Biopharmaceuticals has reported losses of CNY 279 million, CNY 283 million, and CNY 93.62 million for the years 2023, 2024, and the first half of 2025, respectively [6] - A recent report from Softbank China has given Pagoda Biopharmaceuticals a strong buy rating with a target price of HKD 101.80, citing the clinical advantages of PB-119 and potential revenue growth from 2026 to 2029 [6]

Core Viewpoint - Pagoda Biopharma-B (02565.HK) opened over 7% higher, indicating strong market interest and positive investor sentiment [2] Group 1 - The stock price increased by 7.03%, reaching 70 HKD [2] - The trading volume was 770,000 HKD, reflecting active market participation [2]

Core Viewpoint - The stock of Pagoda Biopharma-B (02565) opened over 7% higher, reflecting positive market sentiment following the announcement of a lock-up extension by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [1] Group 1: Stock Performance - Pagoda Biopharma-B's stock rose by 7.03%, reaching HKD 70, with a trading volume of HKD 770,000 [1]. Group 2: Lock-up Extension - The cornerstone investor has agreed not to reduce their holdings of relevant H-shares from the end of the original lock-up period until December 31, 2025, indicating confidence in the company's future prospects [1]. Group 3: Product Approval and Market Potential - The National Medical Products Administration has approved the new drug application for the company's core product PB-119, which is expected to drive significant revenue growth from 2026 to 2029 due to its clinical advantages in treating T2DM and weight loss [1]. - The DCF valuation suggests substantial upside potential for the company, with PB-119 demonstrating outstanding safety and long-lasting effects, particularly suitable for elderly diabetes patients, positioning it as a best-in-class option [1].

Core Viewpoint - The company has received notification from its cornerstone investor, Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., agreeing to extend the lock-up period for its H shares until December 31, 2025, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor will not reduce its holdings in any related H shares from the expiration of the original lock-up period [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

Core Viewpoint - The announcement highlights the extension of the lock-up period for cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1: Lock-up Agreement - The company entered into a cornerstone investment agreement with Yizhe Kangrui Pharmaceutical, which includes a lock-up commitment for a total of 9,584,500 H shares for a period of 6 months from the listing date [1] - The cornerstone investor currently holds 9,584,500 H shares, representing approximately 3.43% of the company's total issued H shares [1] Group 2: Extension of Lock-up Period - The cornerstone investor has agreed not to reduce their holdings of the relevant H shares from the end of the original lock-up period until December 31, 2025 [1] - The company interprets the extension of the lock-up period as a sign of the cornerstone investor's confidence in the company's ability to advance its technological research and achieve significant clinical milestones [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 自願公告 有關基石投資者作出自願延長禁售期的通知 本公告由派格生物醫藥（杭州）股份有限公司（「本公司」）自願刊發。 茲提述本公司日期為2025年5月19日的招股章程及本公司日期為2025年5月26日 的最終發售價及配發結果公告，內容有關（其中包括）(i)本公司與益澤康瑞醫藥 （香港）有限公司（「基石投資者」）訂立的基石投資協議；及(ii)基石投資者就合共 9,584,500股本公司H股作出自上市日期（包括該日）起計六個月期間（「原禁售期」） 的禁售承諾。原禁售期的最後一天為2025年11月26日。截至本公告日期，基石投 資者合共持有9,584,500股H股，佔本公司已發行H股總數約3.43%（「相關H股」）。 近日，本公司接獲基石投資者的通知，據此，基石投資者同意自原禁售 ...